Regulation of nuclear receptor activities by two human papillomavirus type 18 oncoproteins, E6 and E7

Biochemical and Biophysical Research Communications

Volumn 303, Issue 3, 2003, Pages 932-939

  Wang, Wei Ming ^a   Chung, Min Huey ^b   Huang, Shih Ming ^b  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

GRIP1; HPV oncoproteins; Nuclear receptor; p53; Transcription regulation

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR; ONCOPROTEIN; PROTEIN E6; PROTEIN E7; THYROID RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; WART VIRUS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS;

EID: 0037432638     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00444-3     Document Type: Article

References (44)

1. Barbosa M.S. The oncogenic role of human papillomavirus proteins. Crit. Rev. Oncog. 7:1996;1-18.
2. Dell G., Gaston K. Human papillomaviruses and their role in cervical cancer. Cell Mol. Life Sci. 58:2001;1923-1942.
3. Brentjens M.H., Yeung-Yue K.A., Lee P.C., Tyring S.K. Human papillomavirus: a review. Dermatol. Clin. 20:2002;315-331.
4. Dyson N., Howley P.M., Munger K., Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 243:1989;934-937.
5. Munger K., Scheffner M., Huibregtse J.M., Howley P.M. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv. 12:1992;197-217.
6. Werness B.A., Levine A.J., Howley P.M. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 248:1990;76-79.
7. Thomas M., Pim D., Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene. 18:1999;7690-7700.
8. Wu E.W., Clemens K.E., Heck D.V., Munger K. The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein. J. Virol. 67:1993;2402-2407.
9. Jones D.L., Munger K. Interactions of the human papillomavirus E7 protein with cell cycle regulators. Semin. Cancer Biol. 7:1996;327-337.
10. Enmark E., Gustafsson J.A. Orphan nuclear receptors - the first eight years. Mol. Endocrinol. 10:1996;1293-1307.
11. Edwards D.P. Coregulatory proteins in nuclear hormone receptor action. Vitam. Horm. 55:1999;165-218.
12. Chakravarti D., LaMorte V.J., Nelson M.C., Nakajima T., Schulman I.G., Juguilon H., Montminy M., Evans R.M. Role of CBP/P300 in nuclear receptor signalling. Nature. 383:1996;99-103.
13. Blanco J.C., Minucci S., Lu J., Yang X.J., Walker K.K., Chen H., Evans R.M., Nakatani Y., Ozato K. The histone acetylase PCAF is a nuclear receptor coactivator. Genes Dev. 12:1998;1638-1651.
14. Bannister A.J., Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature. 384:1996;641-643.
15. Chen H., Lin R.J., Schiltz R.L., Chakravarti D., Nash A., Nagy L., Privalsky M.L., Nakatani Y., Evans R.M. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell. 90:1997;569-580.
16. Spencer T.E., Jenster G., Burcin M.M., Allis C.D., Zhou J., Mizzen C.A., McKenna N.J., Oñate S.A., Tsai S.Y., Tsai M.-J., O'Malley B.W. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature. 389:1997;194-198.
17. Sterner D.E., Berger S.L. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 64:2000;435-459.
18. Yu C.L., Driggers P., Barrera-Hernandez G., Nunez S.B., Segars J.H., Cheng S. The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. Biochem. Biophys. Res. Commun. 239:1997;617-620.
19. Liu G., Schwartz J.A., Brooks S.C. p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE. Biochem. Biophys. Res. Commun. 264:1999;359-364.
20. Bhat M.K., Yu C., Yap N., Zhan Q., Hayashi Y., Seth P., Cheng S. Tumor suppressor p53 is a negative regulator in thyroid hormone receptor signaling pathways. J. Biol. Chem. 272:1997;28989-28993.
21. Shenk J.L., Fisher C.J., Chen S.Y., Zhou X.F., Tillman K., Shemshedini L. p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR a. J. Biol. Chem. 276:2001;38472-38479.
22. Seto E., Usheva A., Zambetti G.P., Momand J., Horikoshi N., Weinmann R., Levine A.J., Shenk T. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA. 89:1992;12028-12032.
23. Martin D.W., Munoz R.M., Subler M.A., Deb S. p53 binds to the TATA-binding protein-TATA complex. J. Biol. Chem. 268:1993;13062-13067.
24. Murphy M., Ahn J., Walker K.K., Hoffman W.H., Evans R.M., Levine A.J., George D.L. Transcriptional repression by wild-type p53 utilizes histone deacetylases mediated by interaction with mSin3a. Genes Dev. 13:1999;2490-2501.
25. Juan L.J., Shia W.J., Chen M.H., Yang W.M., Seto E., Lin Y.S., Wu C.W. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 275:2000;20436-20443.
26. Sengupta S., Vonesch J.L., Waltzinger C., Zheng H., Wasylyk B. Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J. 19:2000;6051-6064.
27. Sengupta S., Wasylyk B. Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2. Genes Dev. 15:2001;2367-2380.
28. Huang S.M., Stallcup M.R. Mouse Zac1, a transcriptional coactivator and repressor for nuclear receptors. Mol. Cell Biol. 20:2000;1855-1867.
29. Huang S.M., Schonthal A.H., Stallcup M.R. Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1. Oncogene. 20:2001;2134-2143.
30. Chen D., Ma H., Hong H., Koh S.S., Huang S.-M., Schurter B.T., Aswad D.W., Stallcup M.R. Regulation of transcription by a protein methyltransferase. Science. 284:1999;2174-2177.
31. Kao W.H., Beaudenon S.L., Talis A.L., Huibregtse J.M., Howley P.M. Human papillomavirus type16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase. J. Virol. 74:2000;6408-6417.
32. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., Scanlan T.S. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science. 277:1997;1508-1510.
33. Umesono K., Evans R.M. Determinants of target gene specificity for steroid/thyroid hormone receptors. Cell. 57:1989;1139-1146.
34. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
35. Brinkmann A.O., Faber P.W., van Rooij H.C.J., Kuiper G.G.J.M., Ris C., Klaassen P., van der Korput J.A.G.M., Voorhorst M.M., van Laar J.H., Mulder E., Trapman J. The human androgen receptor: domain structure, genomic organization and regulation of expression. J. Steroid Biochem. Mol. Biol. 34:1989;307-310.
36. Green S., Issemann I., Sheer E. A versatile in vivo and in vitro eukaryotic expression vector for protein engineering. Nucleic Acids Res. 16:1988;369.
37. Webb P., Nguyen P., Shinsako J., Anderson C., Feng W., Nguyen M.P., Chen D., Huang S.M., Subramanian S., McKinerney E., Katzenellenbogen B.S., Stallcup M.R., Kushner P.J. Estrogen receptor Activation Function 1 works by binding p160 coactivator proteins. Mol. Endocrinol. 12:1998;1605-1618.
38. Feng W., Ribeiro R.C.J., Wagner R.L., Nguyen H., Apriletti J.W., Fletterick R.J., Baxter J.D., Kushner P.J., West B.L. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science. 280:1998;1747-1749.
39. Ma H., Hong H., Huang S.M., Irvine R.A., Webb P., Kushner P.J., Coetzee G.A., Stallcup M.R. Multiple signal input and output domains of the 160-kDa nuclear receptor coactivator proteins. Mol. Cell Biol. 19:1999;6164-6173.
40. Rosner B. Fundamental of Biostatistics. third ed. 1990;503-526 PSW-KENT Publishing Company, Boston.
41. Bubulya A., Zhou X.F., Shen X.Q., Fisher C.J., Shemshedini L. c-Jun targets amino terminus of androgen receptor in regulating androgen-responsive transcription. Endocrine. 13:2000;55-62.
42. Patel D., Huang S.M., Baglia L.A., McCance D.J. The E6 protein of human papillomavirus type16 binds to and inhibits co-activation by CBP and p300. EMBO J. 18:1999;5061-5072.
43. Kobayashi Y., Kitamoto T., Masuhiro Y., Watanabe M., Kase T., Metzger D., Yanagisawa J., Kato S. p300 mediates functional synergism between AF-1 and AF-2 of estrogen receptor alpha and beta by interacting directly with the N-terminal A/B domains. J. Biol. Chem. 275:2000;15645-15651.
44. Nawaz Z., Lonard D.M., Smith C.L., Lev-Lehman E., Tsai S.Y., Tsai M.J., O'Malley B.W. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol. Cell Biol. 19:1999;1182-1189.